Literature DB >> 12217642

Amino acid and protein targets of 1,2-diacetylbenzene, a potent aromatic gamma-diketone that induces proximal neurofilamentous axonopathy.

Min-Sun Kim1, Seyed B Hashemi, Peter S Spencer, Mohammad I Sabri.   

Abstract

The gamma-diketone analogs 1,2-diacetylbenzene (1,2-DAB) and 2,5-hexanedione (2,5-HD), but not the delta-diketone 1,3-diacetylbenzene (1,3-DAB) or the beta-diketone 2,4-hexanedione, induce neuropathological changes in the rodent central and peripheral nervous systems. The molecular targets of these neurotoxic aromatic and aliphatic gamma-diketones, and of their nonneurotoxic structural analogs and ninhydrin, are examined by assessing their differential reactivity with neural and nonneural amino acids and proteins in vitro and in vivo. Whereas 1,2-DAB is chromogenic and forms polymers with amino acids (notably lysine) and proteins (especially lysine-rich proteins), 1,3-DAB lacks these properties. Ninhydrin forms a chromophore without evidence of protein polymerization. 1,2-DAB preferentially targets neurofilament over microtubule protein in vitro and in situ. Based on protein reactivity, 1,2-DAB is three orders of magnitude more reactive than 2,5-HD. Lysine-rich neurofilament protein subunits NF-H and NF-M are more susceptible than lysine-poor NF-L and beta-tubulin to 1,2-DAB. These observations correlate with the development of proximal (1,2-DAB) and distal (2,5-HD) neurofilament-filled axonal swellings and segregated intact microtubules observed during systemic treatment with aromatic and aliphatic gamma-diketones.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217642     DOI: 10.1006/taap.2002.9456

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  9 in total

1.  Monocyclic and dicyclic hydrocarbons: structural requirements for proximal giant axonopathy.

Authors:  Desire D Tshala-Katumbay; Valerie S Palmer; Michael R Lasarev; Robert J Kayton; Mohammad I Sabri; Peter S Spencer
Journal:  Acta Neuropathol       Date:  2006-07-28       Impact factor: 17.088

Review 2.  Neuroprotein Targets of γ-Diketone Metabolites of Aliphatic and Aromatic Solvents That Induce Central-Peripheral Axonopathy.

Authors:  Peter S Spencer
Journal:  Toxicol Pathol       Date:  2020-03-12       Impact factor: 1.902

Review 3.  Toxic Peripheral Neuropathies: Agents and Mechanisms.

Authors:  William M Valentine
Journal:  Toxicol Pathol       Date:  2019-06-10       Impact factor: 1.902

4.  Therapeutic effect of the combined use of growth hormone releasing peptide-6 and epidermal growth factor in an axonopathy model.

Authors:  Diana García Del Barco; Héctor Pérez-Saad; Valia Rodríguez; Javier Marín; Viviana Falcón; Jorge Martín; Danay Cibrian; Jorge Berlanga
Journal:  Neurotox Res       Date:  2010-02-19       Impact factor: 3.911

5.  New insights into mechanisms of gamma-diketone-induced axonopathy.

Authors:  Desire Tshala-Katumbay; Paul Desjardins; Mohammad Sabri; Roger Butterworth; Peter Spencer
Journal:  Neurochem Res       Date:  2009-04-29       Impact factor: 3.996

6.  Probing mechanisms of axonopathy. Part I: Protein targets of 1,2-diacetylbenzene, the neurotoxic metabolite of aromatic solvent 1,2-diethylbenzene.

Authors:  Desire Tshala-Katumbay; Victor Monterroso; Robert Kayton; Michael Lasarev; Mohammad Sabri; Peter Spencer
Journal:  Toxicol Sci       Date:  2008-05-22       Impact factor: 4.849

Review 7.  The Role of Protein Adduction in Toxic Neuropathies of Exogenous and Endogenous Origin.

Authors:  Peter S Spencer; Xiao Chen
Journal:  Toxics       Date:  2021-04-29

8.  Axonopathy-inducing 1,2-diacetylbenzene forms adducts with motor and cytoskeletal proteins required for axonal transport.

Authors:  Mohammad I Sabri; Seyed B Hashemi; Michael R Lasarev; Peter S Spencer
Journal:  Neurochem Res       Date:  2007-06-19       Impact factor: 4.414

9.  Potential targets for anti-SARS drugs in the structural proteins from SARS related coronavirus.

Authors:  Guang Wu; Shaomin Yan
Journal:  Peptides       Date:  2004-06       Impact factor: 3.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.